Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 51 - 100 of 1868 results
- Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility.
- IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.
- Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
- Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
- Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases.
- Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells.
- Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
- The effects of interleukin-7 on the lymphangiogenic properties of human endothelial cells.
- Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
- Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy.
- IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
- Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes.
- CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen.
- Immature CD4- CD103+ rat dendritic cells induce rapid caspase-independent apoptosis-like cell death in various tumor and nontumor cells and phagocytose their victims.
- Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways.
- Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
- CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells.
- Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
- Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics.
- Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
- Efficient infection of tumor endothelial cells by a capsid-modified adenovirus.
- A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.
- Antibody against vascular endothelial growth factor (VEGF) inhibits angiogenic switch and liver metastasis in orthotopic xenograft model with site-dependent expression of VEGF.
- Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.
- Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.
- Turning on/off tumor-specific CTL response during progressive tumor growth.
- Epigallocatechin-3-gallate impairs chemokine production in human colon epithelial cell lines.
- Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells.
- Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.
- Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.
- Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells.
- Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
- Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8.
- Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo.
- Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice.
- Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
- A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.
- A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
- Dynamic DNA methylation and histone modifications contribute to lentiviral transgene silencing in murine embryonic carcinoma cells.
- Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
- Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.
- Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
- A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone.
- Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.
- Cellular factors influencing Semliki Forest Virus vector biology.
- HSV-1-based amplicon vectors: design and applications.
- Current issues in adeno-associated viral vector production.
- Adenovirus as vehicle for anticancer genetic immunotherapy.
- Biology and application of alphaviruses in gene therapy.
- Development and application of replication-incompetent HSV-1-based vectors.